|
DE60037394T2
(de)
*
|
1999-01-29 |
2009-01-02 |
The Board Of Trustees For The University Of Illinois, Urbana |
VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
|
|
AU7887501A
(en)
*
|
2000-07-06 |
2002-01-21 |
Us Gov Health & Human Serv |
Tetrahydrobenzothiazole analogues as neuroprotective agents
|
|
AU2001294515A1
(en)
*
|
2000-08-11 |
2002-02-25 |
The Regents Of The University Of California |
Use of stat-6 inhibitors as therapeutic agents
|
|
US6696441B1
(en)
|
2000-08-11 |
2004-02-24 |
The Regents Of The University Of California |
Inhibition of p53-induced stress response
|
|
US6861431B2
(en)
|
2001-03-23 |
2005-03-01 |
The Board Of Trustees Of The University Of Illinois |
Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
|
|
US7601846B2
(en)
|
2001-06-26 |
2009-10-13 |
The Regents Of The University Of California |
Compounds having activity as inhibitors of apoptosis
|
|
US20040198783A1
(en)
*
|
2003-04-03 |
2004-10-07 |
Semafore Pharmaceuticals Inc. |
Targeted bone marrow protection agents
|
|
WO2004089345A1
(en)
*
|
2003-04-03 |
2004-10-21 |
Semafore Pharmaceuticals Inc. |
Bone targeting of biodegradable drug-containing nanoparticles
|
|
US7657893B2
(en)
*
|
2003-04-23 |
2010-02-02 |
International Business Machines Corporation |
Accounting method and logic for determining per-thread processor resource utilization in a simultaneous multi-threaded (SMT) processor
|
|
US7132421B2
(en)
*
|
2003-06-17 |
2006-11-07 |
Hoffmann-La Roche Inc. |
CIS-imidazoles
|
|
CN1871341A
(zh)
*
|
2003-08-20 |
2006-11-29 |
悉尼北方和中部海岸区医疗服务系统 |
提高胚胎生存力的方法
|
|
EP1781315B1
(en)
|
2004-08-23 |
2015-01-07 |
Yeda Research And Development Co., Ltd. |
Peptide inhibitors for mediating stress responses
|
|
EP1799269B1
(en)
*
|
2004-09-28 |
2016-09-07 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
|
|
WO2006055672A2
(en)
*
|
2004-11-16 |
2006-05-26 |
Limerick Neurosciences, Inc. |
Methods and compositions for treating pain
|
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
|
KR100877824B1
(ko)
*
|
2005-11-11 |
2009-01-12 |
한국생명공학연구원 |
Ｅ2ｅｐｆ ｕｃｐ-ｖｈｌ 상호작용 및 그 용도
|
|
US9066976B2
(en)
|
2005-11-11 |
2015-06-30 |
Korea Research Institute Of Bioscience And Biotechnology |
Method for therapeutic angiogenesis
|
|
US20070110756A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Reinberg Danny F |
Method for modulating P53 activity via methylation
|
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US7910566B2
(en)
*
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
|
KR20090090383A
(ko)
*
|
2006-12-14 |
2009-08-25 |
다이이찌 산쿄 가부시키가이샤 |
이미다조티아졸 유도체
|
|
FR2910895B1
(fr)
*
|
2006-12-29 |
2010-08-27 |
Biopharmed |
"derives d'imino-tetrahydrobenzotriazoles ayant des proprietes anti-migratoires de metastases met dependantes"
|
|
CA2939778C
(en)
|
2007-01-31 |
2019-01-29 |
Dana-Farber Cancer Institute, Inc. |
Stabilized p53 peptides and uses thereof
|
|
CA2682174C
(en)
|
2007-03-28 |
2021-04-06 |
President And Fellows Of Harvard College |
Stitched polypeptides
|
|
HRP20140522T1
(hr)
*
|
2007-06-27 |
2014-08-15 |
Quark Pharmaceuticals, Inc. |
Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
|
|
KR101606943B1
(ko)
|
2008-06-27 |
2016-03-28 |
고쿠리츠 다이가쿠 호진 교토 다이가쿠 |
유도된 다능성 줄기 세포의 효율적인 확립 방법
|
|
JP2012504646A
(ja)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
CN102231983A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
US20110288155A1
(en)
|
2008-12-18 |
2011-11-24 |
Elena Feinstein |
Sirna compounds and methods of use thereof
|
|
CA2761896A1
(en)
|
2009-05-13 |
2010-11-18 |
The University Of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
CN102625837B
(zh)
|
2009-08-07 |
2015-01-14 |
国立大学法人京都大学 |
有效建立诱导的多能干细胞的方法
|
|
KR20130099938A
(ko)
|
2010-08-13 |
2013-09-06 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티도미메틱 거대고리
|
|
WO2012037283A2
(en)
*
|
2010-09-14 |
2012-03-22 |
Mount Sinai School Of Medicine |
Admimistration of sns neuroprotective agents to promote hematopoietic regeration
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
US20140088017A1
(en)
|
2011-05-23 |
2014-03-27 |
Yeda Research And Development Co., Ltd. |
Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
|
|
WO2013022946A1
(en)
*
|
2011-08-09 |
2013-02-14 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating dna damage
|
|
CN104039342A
(zh)
|
2011-10-18 |
2014-09-10 |
爱勒让治疗公司 |
拟肽大环化合物
|
|
NZ627528A
(en)
|
2012-02-15 |
2016-05-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
HK1205454A1
(en)
|
2012-02-15 |
2015-12-18 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
|
EP2895608B1
(en)
|
2012-09-12 |
2018-12-05 |
Quark Pharmaceuticals, Inc. |
Double-stranded oligonucleotide molecules to p53 and methods of use thereof
|
|
SG11201503052RA
(en)
|
2012-11-01 |
2015-05-28 |
Aileron Therapeutics Inc |
Disubstituted amino acids and methods of preparation and use thereof
|
|
US20140271460A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly Active Anti-Neoplastic and Anti-Proliferative Agents
|
|
US9527857B2
(en)
|
2013-03-15 |
2016-12-27 |
GI Therapeutics, Inc. |
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
|
|
US10314826B2
(en)
|
2014-02-07 |
2019-06-11 |
University Of Maryland, Baltimore |
Methods of treatment of ischemia-induced angiogenesis and arteriogenesis
|
|
WO2015161283A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
|
|
HUE054226T2
(hu)
|
2014-05-29 |
2021-08-30 |
Quark Pharmaceuticals Inc |
Módszerek és készítmények az ischaemia reperfúziós károsodás megelõzésére a szervekben
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
MX389354B
(es)
|
2014-09-24 |
2025-03-20 |
Aileron Therapeutics Inc |
Macrociclos peptidomimeticos y formulaciones de los mismos.
|
|
MX2017003797A
(es)
|
2014-09-24 |
2017-06-15 |
Aileron Therapeutics Inc |
Macrociclos peptidomimeticos y usos de los mismos.
|
|
WO2016154058A1
(en)
|
2015-03-20 |
2016-09-29 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
JP2018528217A
(ja)
|
2015-09-10 |
2018-09-27 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
|
|
US20190015393A1
(en)
*
|
2016-01-18 |
2019-01-17 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse
|
|
WO2018083606A1
(en)
|
2016-11-01 |
2018-05-11 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
WO2020023502A1
(en)
|
2018-07-23 |
2020-01-30 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
WO2020206046A1
(en)
|
2019-04-01 |
2020-10-08 |
The Broad Institute, Inc. |
Methods and compositions for cell therapy
|
|
US20220251054A1
(en)
*
|
2019-06-03 |
2022-08-11 |
The Regents Of The University Of California |
Analogues and Methods of Treating Rett Syndrome
|
|
JP7429035B2
(ja)
*
|
2019-08-01 |
2024-02-07 |
東京都公立大学法人 |
機能不全ミトコンドリアを消去するための複合体、および細胞老化を抑制するための複合体
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
IL319222A
(en)
|
2022-09-06 |
2025-04-01 |
Max Planck Gesellschaft Zur F?Rderung Der Wss E V |
Engineering SOX/OCT heterodimerization to induce high-level developmental initiation
|